Orgenesis, a developer, manufacturer and service provider of advanced cell therapies, has entered into a collaboration and licensing agreement with ExcellaBio for certain technologies developed by Sabina Glozman, Ph.D., including an exosome-like membrane nanostructure (Bioxome) and related processes for the production of exosomes/extracellular vesicles (EVs).  Under the agreement, Orgenesis will have the exclusive, worldwide rights to certain commercial applications of the technology arising fro...